Actively Recruiting
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Led by Peter Humaidan · Updated on 2026-04-22
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Peter Humaidan
Lead Sponsor
H
Herlev Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Female infertility is a significant challenge that is expected to worsen with delayed parenthood. Researchers are studying the role of receptor activator of NF-baB ligand (RANKL) in ovarian function and follicle development. This research explores whether blocking RANKL, using an antibody called denosumab which is currently used for osteoporosis, can help improve egg maturation and ovarian health in women undergoing fertility treatments. The study involves two main groups: one receiving denosumab and the other receiving PBS as a comparison. It will test how modifying RANKL affects ovarian function in mice, monkeys, and human ovarian tissue, both systemically and locally. The research aims to clarify RANKL's role at different stages of follicle development and assess if manipulating this pathway can optimize in vitro egg maturation and fertility treatments. Participants, who are adult women with normal ovarian reserve, will be involved in evaluations including ovarian tissue studies and reproductive assessments. Researchers will monitor the impact of RANKL modification on ovarian function and follicle maturation throughout the study. The main measurements include reproductive characteristics in various animal models and human ovarian tissue to determine the effects of denosumab treatment from enrollment to study completion.
CONDITIONS
Brief Title
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Normal AMH-value indicating normal ovarian reserve
- Able to give consent to participate
You will not qualify if you...
- History of autotransplanted ovarian tissue
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From enrollment to the end of the study
Participants receive either Denosumab or PBS medical preparation to facilitate maturation of immature oocytes during folliculogenesis.
Visits scheduled throughout the treatment period as determined by the study team
Trial Site Locations
Total: 1 location
1
Regionshospitalet, Skive, Midt Jylland 7800
Skive, Midt Jylland, Denmark, 7800
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here